Cytiva process development services help biotech companies accelerate their molecules through clinical development. With global reach and deep scientific expertise, we offer solutions and delivery technologies across diverse modalities. These include recombinant proteins, monoclonal antibodies (mAbs), viral vectors, plasmid DNA (pDNA) and messenger RNA (mRNA).
Our experienced scientists will work closely with you to set goals and manage your projects of any size with full transparency. We will support your molecule’s manufacturability, upskill your team with training and education, and transfer all process knowledge to you until we cross the finish line together.
Think of us as an extension of your team.
- Integrated end-to-end solutions for process development, optimization, and scale-up
- Equipment, skilled staff, and capacity to help you shrink development timelines and maximize portfolio value
- 35+ years of proven expertise to accelerate your pipeline
- Fast Trak training courses covering various topics from upstream to downstream
Visit our website: https://www.cytivalifesciences.com/en/in/services/process-development
BROCHURES AND DATASHEETS
CONTACT INFORMATION
Cytiva
100 Results Way
Marlborough, MA 08855-1327
UNITED STATES
Phone: 800-526-3593
FEATURED ARTICLES
-
Accelerate drug development and reduce risk with parallel operations. Learn how leveraging CDMO partnerships while building internal capabilities can cut costs and speed your path to market.
-
Accelerating biologics development requires more than speed. Discover how the right CDMO partnership can streamline processes and help you reach the market faster without sacrificing control.
-
Transparency and collaboration with a CDMO are vital for reducing risk and protecting IP. Discover four essential practices, from clear communication to IP safeguards, that help build trust.
-
Parallel operations with a CDMO can reduce risk and accelerate timelines by enabling simultaneous process development and manufacturing. Learn how this approach supports facility design.
-
Balancing robust analytics and clinical readiness is key for early-phase pDNA and mRNA therapeutics amid structural complexity and regulatory challenges.
-
Venture capital in biotech remains strong post-pandemic, especially in cell and gene therapies. Discover five key factors to help companies choose between in-house and outsourced process development strategies.
-
The biosimilars market is suddenly booming, with established biopharma giants and nimble start-ups all clamoring for a piece of the action. But such steep competition means that only the wise will survive.
-
A well-executed bioprocess technology transfer is critical to ensure smooth knowledge transfer and optimal process reproducibility.